

6<sup>th</sup> World Congress on

# Mental Health, Psychiatry and Wellbeing

March 20-21, 2019 | New York, USA

ACCEPTED ABSTRACTS

INTERNATIONAL JOURNAL OF EMERGENCY MENTAL HEALTH AND HUMAN RESILIENCE 2019, VOLUME 21

DOI: 10.4172/1522-4821-C2-030

## Rediscovering clozapine

**Jason A. Gross**Pharmaceutical Executive,  
Canada

In 1989, clozapine was approved in the United States for Treatment-Resistant Schizophrenia (TRS), which after thirty years of use is still the only

known treatment for TRS. In the United States, there are more than 3.5 million people living with schizophrenia, of which approximately 1 million have what is known as treatment-resistant schizophrenia. However, this treatment option is only offered to about 3% of eligible TRS patients are receiving treatment

with clozapine. This lecture will explore the: (i) The perceived barriers to clozapine use (ii) Recent advances in clozapine care (iii) New technology for monitoring patients with TRS treated with clozapine (iv) Explore best practices for patients with TRS.

[j.gross@hlstherapeutics.com](mailto:j.gross@hlstherapeutics.com)